Who is sponsoring NCT06762431?

NCT06762431 is sponsored by Vitebsk Regional Clinical Cancer Centre.

What drugs are being tested in NCT06762431?

Interventions in NCT06762431: Lenalidomide, Lenalidomide.

What condition does NCT06762431 study?

NCT06762431 studies Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL).

Is NCT06762431 still recruiting?

NCT06762431 is currently enrolling by invitation. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT06762431: VTB-CLL002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

ENROLLING BY INVITATION Phase 1, PHASE2 Last updated 7 January 2025

What this trial tests

Phase 1, PHASE2 trial testing Lenalidomide in Chronic Lymphocytic Leukaemia (CLL) in 60 participants. Enrolling by invitation.

Timeline

4 November 2024

Primary endpoint
9 March 2026

31 August 2026

Quick facts

Lead sponsor	Vitebsk Regional Clinical Cancer Centre
Phase	Phase 1, PHASE2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	4 November 2024
Primary completion	9 March 2026
Estimated completion	31 August 2026
Sites	1 location across Belarus

Drugs / interventions tested

Lenalidomide — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Chronic Lymphocytic Leukaemia (CLL) — all drugs for Chronic Lymphocytic Leukaemia (CLL) →
Small Lymphocytic Lymphoma (SLL) — all drugs for Small Lymphocytic Lymphoma (SLL) →

Sponsor

Vitebsk Regional Clinical Cancer Centre

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies.
Rao A, Darwish C, Campbell KS, Khanal R, et al · · 2026 · PMID 42093982 · DOI 10.3389/fimmu.2026.1727926
Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas.
Tang W, Yu S. · · 2026 · PMID 41993181 · DOI 10.3389/fimmu.2026.1792910
Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy.
Yi R, Zhang Z, Yang Y, Zhu H. · · 2026 · PMID 41978748 · DOI 10.1002/cai2.70053

Verify or expand the search:

Other trials of Lenalidomide

Trials testing the same drug.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07247097 — ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred · Phase 2 · not yet recruiting
NCT07465029 — A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting
NCT06910124 — Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Neg · Phase 2 · recruiting

Other recruiting trials for Chronic Lymphocytic Leukaemia (CLL)

Currently open trials in the same condition.

NCT05645172 — Retention Rate of Acalabrutinib in a Non-interventional Setting · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06762431 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vitebsk Regional Clinical Cancer Centre
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06762431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing